You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Expert Perspectives in Renal Cell Carcinoma: Sharing Patient Case Insights in Treatment Sequencing

  • Authors: Thomas Powles, MBBS, MRCP, MD; Manuela Schmidinger, MD; David Cella, PhD
  • CPD Released: 4/28/2022
  • Valid for credit through: 4/28/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically the oncology care team, urologists and any other healthcare specialists involved in the care of patients with renal cell carcinoma (RCC).

The goal of this activity is for the learner to improve their knowledge and competence in the management of RCC across the continuum of disease in order to maximize outcomes for the individual patient.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical evidence supporting optimal treatment strategies across the disease continuum of advanced RCC
  • Have greater competence related to
    • Sequencing RCC therapies based on patient-, disease- and prior therapy-related factors
    • Effective management of treatment-related adverse events


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Thomas Powles, MBBS, MRCP, MD

    Professor of Genitourinary Oncology
    Barts Cancer Institute
    Queen Mary University of London
    London, United Kingdom

    Disclosures

    Disclosure: Thomas Powles, MBBS, MRCP, MD, has the following relevant financial relationships:
    Consultant or advisor for: Astellas; AstraZeneca; Bristol Myers Squibb Company; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Roche; Seagen Inc., formerly Seattle Genetics, Inc.
    Research funding from: Astellas; AstraZeneca; Bristol Myers Squibb Company; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Roche; Seagen Inc., formerly Seattle Genetics, Inc.
    Other: Travel expenses from: AstraZeneca; Ipsen; Merck Sharp & Dohme, Corp.; Pfizer; Roche

  • Manuela Schmidinger, MD

    Professor of Medicine
    Medical University of Vienna
    Vienna, Austria

    Disclosures

    Disclosure: Manuela Schmidinger, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb Company; Eisai; Exelixis; EUSA; Merck; Merck Sharp & Dohme, Corp.; Pfizer
    Contracted researcher for: Exelixis; Ipsen; Merck; Merck Sharp & Dohme, Corp.; Pfizer
    Other: Honoraria for lectures from: Bristol Myers Squibb Company; Eisai; Exelixis; EUSA; Ipsen; Merck Sharp & Dohme, Corp.

  • David Cella, PhD

    Ralph Seal Paffenbarger Professor and Chair
    Department of Medical Social Sciences
    Feinberg School of Medicine
    Northwestern University
    Chicago, Illinois, United States

    Disclosures

    Disclosure: David Cella, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Astellas; Ayala; Bristol Myers Squibb Company; Celcuity; Evidera; Fulcrum; Ipsen; Merck; Novartis; Pfizer
    Research funding from: Bayer; Boehringer Ingelheim; Bristol Myers Squibb Company; Clovis; Fulcrum; GlaxoSmithKline; Novartis

Editors

  • Keisha Peters, MSc

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Disclosure: Keisha Peters, MSc has no relevant financial relationships. 

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC 

    Disclosures

    Disclosure: Chii Shyang Fong, PhD has no relevant financial relationships. 

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Expert Perspectives in Renal Cell Carcinoma: Sharing Patient Case Insights in Treatment Sequencing

Authors: Thomas Powles, MBBS, MRCP, MD; Manuela Schmidinger, MD; David Cella, PhDFaculty and Disclosures

CPD Released: 4/28/2022

Valid for credit through: 4/28/2023

processing....

Educational Impact Challenge

The goal of this activity is for the learner to improve their knowledge and competence in the management of RCC across the continuum of disease in order to maximize outcomes for the individual patient.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print